Carregant...

Methotrexate Re-Challenge for Recurrent Primary Central Nervous System Lymphoma

BACKGROUND: The prognosis of primary CNS lymphoma (PCNSL) recurring after methotrexate is poor (objective response rates [ORR] = 26%–53%; 1-year overall survival [OS] = 35%–57%). Salvage PCNSL chemotherapies have been based on the use of different agents to avoid cross-resistance; however, methotrex...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Neurooncol
Autors principals: Pentsova, Elena, DeAngelis, Lisa M., Omuro, Antonio
Format: Artigo
Idioma:Inglês
Publicat: 2014
Matèries:
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5256683/
https://ncbi.nlm.nih.gov/pubmed/24481997
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11060-014-1370-0
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!